BPC-157 and TB-500 Together: Blends, Stacks and the HHS Single-Ingredient Rule

BPC-157 and TB-500 are sold together as a “recovery” stack, often pre-mixed in one vial, and the “Glow” and “Klow” blends add GHK-Cu and KPV on top. No controlled human trial has tested any of these combinations. The one published study that reports patients given both had four of them, in a chart review from a single clinic.^[7] The new HHS compounding policy does not help a blend either. It requires that a compounded product contain “only a single Active Pharmaceutical Ingredient,” so a pre-mixed vial falls outside it, and GHK-Cu is not on the policy’s list at all.^[1]

What the blends contain

The stack most people search for pairs BPC-157, a 15-amino-acid peptide first described in 1993, with TB-500, a lab-made seven-amino-acid fragment of the repair protein thymosin beta-4.^[1][2][3] Sellers offer the two as separate vials meant to be used together, or as one pre-mixed vial. The names on top of that are marketing, not standard formulas. “Glow” usually means GHK-Cu, BPC-157 and TB-500 in one vial; “Klow” is the same three plus KPV. KPV alone is covered only as a capsule or cream (oral and topical KPV). The amount of each peptide differs from seller to seller.

FDA found the same products when it reviewed these peptides for the July 2026 advisory committee. Its BPC-157 review describes websites selling BPC-157 with TB-500 as a “multiple-API” injection, as a nasal spray, and as “research purposes only” vials.^[2] Its KPV review found KPV promoted alongside BPC-157, TB-500 and two other substances as a “regenerative combo” for muscle and joint repair.^[4] On prescription menus the pairing is common too. Of the telehealth sellers we track with a peptide menu, 15 list both BPC-157 and TB-500.

What has been tested, together and apart

Start with the parts. FDA found no clinical study or human exposure data for TB-500 by any route.^[3] For KPV it found no published study in which any product containing it was given to people.^[4] Injected GHK-Cu has little human data; FDA’s safety page says “there are limited data in humans.”^[5] BPC-157 has the most, and it is still thin. FDA counted five small clinical reports: enema studies in healthy volunteers and in ulcerative colitis, a bladder study, an IV infusion study in two people, and the knee chart review described below.^[2]

The combination has less. The one human report comes from a Florida clinic that looked back over a year of charts for patients who had a peptide injected into the knee. Sixteen patients answered a phone survey. Twelve had received BPC-157 alone, and four had received BPC-157 with “TB4.” Three of those four said their pain improved significantly; one had no relief.^[7] There was no control group and no standard pain scale; the authors write that “no specific tools were used to measure their improvement.”^[7] The paper also does not make clear whether “TB4” meant the full thymosin beta-4 protein or the TB-500 fragment, which FDA treats as different substances.^[3]

An October 2026 review by orthopedic surgeons at NYU Langone and Baptist Health counted that chart review as the entire human musculoskeletal record for BPC-157. Their conclusion: “Routine clinical use cannot be currently recommended.”^[9]

“Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.”^[8]

— Biçer et al., Joint Diseases and Related Surgery, 2026

The only controlled test of the pairing used rats. A Turkish team cut and repaired the Achilles tendon in 32 rats and split them into four groups of eight: no treatment, BPC-157, TB-500, or both. After four weeks only the TB-500 group had significantly stronger tendons than untreated rats. The combination group scored better than untreated rats on one tissue measure, but it did no better than either peptide given alone.^[8] The idea that the two work better together, the premise of every blend, has so far failed the one experiment designed to check it, and that experiment was in animals.

Registered trials are not filling the gap yet. No trial on ClinicalTrials.gov tests BPC-157 with TB-500, and none tests a Glow or Klow blend. The BPC-157 trials listed there test it on its own, such as a University of Arkansas pilot comparing it with saline injections after rotator cuff surgery, which is not yet recruiting.^[11]

Why the HHS policy leaves blends out

On October 28, 2026, HHS said it would not take enforcement action against state-licensed pharmacies and physicians that compound six peptides, including BPC-157, TB-500 and KPV, under section 503A while FDA works through rulemaking.^[1] It is an interim enforcement decision. HHS states that compounded drugs “are not FDA-approved,” the policy does not reach larger 503B outsourcing facilities, and FDA’s own scientists had recommended against listing these peptides.^[1][10] For the full list of conditions, see our guide to the HHS peptide policy.

All ten conditions must be met at once. Condition 7 is the one that rules out a pre-mixed vial:

“The compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A. It will be easier to attribute adverse events or clinical outcomes to a specific substance, which is essential for meaningful safety surveillance and signal detection, if compounded peptide products include a single API.”^[1]

— HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, condition 7

A vial holding BPC-157 and TB-500 together has two active ingredients, so it does not qualify, even though both peptides are on the list. Glow and Klow fail on more than one count. GHK-Cu is not among the six peptides in Appendix A, which means any product containing it misses condition 1 as well.^[1] KPV is covered only as a topical or oral product and TB-500 only as an injection, so no single injectable vial can hold both within the route limits of condition 2.^[1]

The wording of condition 7 is about each compounded product. It does not address a prescriber ordering two separate single-ingredient vials for the same patient; each of those would have to meet all ten conditions on its own, including a patient-specific prescription.^[1] That route says nothing about whether the combination works, and the attribution problem described below follows the patient either way.

Where GHK-Cu stands

GHK-Cu sits under FDA’s older compounding rules, not the HHS policy, and its status depends on the route. Since May 2026 FDA has listed non-injectable GHK-Cu, such as creams, in category 1, its list of nominated substances still under evaluation, and it plans to put GHK-Cu before its advisory committee by the end of February 2027.^[6] Injectable GHK-Cu is not in category 1. FDA’s safety-risk page says compounded injections “may pose risk for immunogenicity” because the peptide can aggregate and can carry peptide-related impurities.^[5] A Glow or Klow vial meant for injection is the form FDA has flagged. Our GHK-Cu evidence review covers the skin and wound studies.

Mixing makes side effects harder to trace

HHS’s reason for condition 7 is practical. When something goes wrong with a two-peptide product, nobody can tell which peptide caused it. FDA’s own adverse event files show this has already happened.

In its BPC-157 review, FDA found three reports in its drug adverse event database, all for injections. In one, a 40-year-old woman injected a “research purposes only” product containing BPC-157 and TB-500 twice daily for joint and wound healing. Within a week she developed diffuse darkening of the skin and gums. She stopped, restarted two weeks later, and the same reaction came back, and it cleared once she quit the peptides entirely.^[2] A reaction that returns on rechallenge is strong evidence that the product caused it. FDA still could not say which ingredient was responsible: “because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs.”^[2]

A second report, injection-site redness and swelling that lasted nine days, came from a woman also injecting compounded thymosin, which FDA said limits what the report can show about BPC-157.^[2] FDA’s food and supplement complaint system held two more cases about “blended TB-500 and BPC-157,” neither with a safety assessment.^[3] For the effects reported with each peptide alone, see BPC-157 side effects and TB-500 side effects.

The HHS policy tries to fix the reporting side. Condition 5 requires compounders to report serious adverse events to FDA’s MedWatch program, and to report each product they make with its active ingredient, strength and original manufacturer.^[1] Until now FDA has noted that 503A compounders “generally do not report adverse events to FDA.”^[2] A report on a single-ingredient vial points to one substance from one maker. A report on a four-peptide blend points to four, and the signal HHS says it wants to catch would be split among them.

What mixing does to quality testing

Condition 3 asks for a certificate of analysis for each bulk peptide, from an FDA-registered facility, covering identity, purity, potency, and contaminants such as endotoxins, heavy metals and microbes. HHS says this is meant to show that “what a compounder receives from a supplier is what it claims to be.”^[1] Each certificate describes one substance from one manufacturer’s lot.

A pre-mixed vial combines two to four of those lots. A certificate for the raw powder of one peptide says nothing about how much of each peptide ends up in the finished blend, or whether they stay intact together in one solution. Orthopedic reviewers already flag “identity, purity, concentration, sterility, and manufacturing consistency” as open questions for single peptides sold online.^[9] With a blend, the buyer has to answer them for every ingredient at once. Our guide to reading a peptide certificate of analysis explains what a real one should show, and research-use-only vs compounded peptides covers why a gray-market vial carries none of these checks.

If you are offered a stack or blend

• Ask whether it is one vial or several. A single vial with more than one peptide is outside the HHS policy, whatever the seller says.^[1]
• Check every ingredient against the six in Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Anything else, including GHK-Cu, is not covered.^[1]
• Ask for a certificate of analysis for each peptide, from an FDA-registered facility, with the facility’s location on it.^[1]
• Check that the label reads “This is a compounded drug product. Not for resale.” and that it explains how to report side effects.^[1]
• If you are on a GLP-1, see peptides alongside a GLP-1 before adding anything.